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Aim: To study indices of energy metabolism, content of K+ and Mg++ both in peripheral blood and in Walker-256 carcinosarcoma 
during development of resistance to doxorubicin. Methods: Resistance of Walker-256 carcinosarcoma to doxorubicin has been 
developed through 12 subsequent transplantations of tumor after the chemotherapy. Parental strain was inhibited by drug by 65%, 
while transitional resistant substrains — by 30% and 2%, respectively. Determination of biochemical indices in blood serum and 
homogenates of tumor tissue, level of potassium, magnesium, lactate, glucose, activities of lactate dehydrogenase and glucose-
6-phosphate dehydrogenase was performed with the help of biochemical and immune-enzyme analyzer GBG ChemWell 2990 (USA) 
using standard kits. Polarography was used to determine indices of mitochondrial oxidative phosphorylation. Study of mitochon-
drial membrane potential was carried out on flow cytometer Beckman Coulter Epics XL using dye JC-1. Results: It has been de-
termined that development of drug resistance causes the decrease of K+, Mg++, glucose content in blood serum and increase of these 
indices in tumor tissue. At the same time, gradual tumor’s loss of sensitivity is characterized by decrease of glycolysis activity 
in it and activation of mitochondrial oxidative phosphorylation and pentose phosphate pathway of glucose degradation, which causes 
more intensive formation of NADPH. Conclusion: Development of drug resistance of tumor causes certain metabolic changes 
in organism and tumor. Further study of such changes will make possible to determine tumor and extratumor markers of resistance.
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Study of pathogenesis of malignant neoplasms both 
in experimental and clinical observations has a great 
theoretical and practical significance. While searching 
metabolic differences between normal and tumor cells, 
researchers have paid attention first of all to those pro-
cesses, which underlie intensity of growth and division 
of cells, and, primarily processes of biosynthesis of nucleic 
acids and anaerobic and aerobic degradation of carbo-
hydrates — glycolysis and mitochondrial oxidative phos-
phorylation. At that time, significant changes in important 
metabolic systems have been observed in tumor cells 
[1–7]. The cause of such changes is the loss by tumor 
cell of some regulatory mechanisms, which act on genetic 
or metabolic level.
Significant role in metabolism of cells is played by wa-
ter-salt metabolism [8–10]. Properties of cells and their 
viability also depend on appropriate ion concentrations. 
Consumption of glucose by cells is always accompanied 
with transfer of potassium from intercellular liquid inside 
cell [9]. In general, biochemical reactions require certain 
composition of medium and maintenance of appropriate 
water-salt balance both in tumor and in organism. This 
issue becomes especially important, when it is spoken 
of occurrence and development of drug resistance 
of malignant tumors. For this reason, in this work we have 
studied important bioenergetics indices, content of K+ and 
Mg++ in both peripheral blood and Walker-256 carcinosar-
coma during development of its resistance to doxorubicin.
MATERIALS AND METHODS
Experimental model. In the study, female rats 
weighting 120–150 g bred in the vivarium of the R.E. Ka-
vetsky Institute of Experimental Pathology, Oncology and 
Radiobiology, NAS of Ukraine (Kyiv, Ukraine), were used. 
As experimental model, Walker-256 carcinosarcoma was 
chosen. Tumor transplantation was performed by subcu-
taneous injection of 20%  Walker-256 carcinosarcoma cell 
suspension in the thigh area. Animals were housed as the 
control (N1) and experimental (N2) groups (nor less than 
10 animals per group). When the volume of tumor reached 
0.5 cm3, six doxorubicin (Ebewe, Austria) injections 
(1.5 mg/kg daily) were administered to the animals of the 
group 2. Then the animals were decapitated under nar-
cosis (Sedazin, Biowet-Pulawy, Poland) according to the 
rules of Ethic Committee; tumors were resected, 20% 
tumor cell suspension was prepared and transplanted 
to the animals from the new control and experimental 
groups. Then doxorubicin therapy was performed by the 
same schedule. In total, 12 courses of tumor transplanta-
tion/doxorubicin therapy were performed.
All studies have been performed during development 
of resistance of Walker-256 carcinosarcoma to doxo-
rubicin. Animals, which underwent removal of tumor 
for the study, have not received cytostatic drug directly. 
Indices of ionic homeostasis and bioenergetics of pa-
rental Walker-256 carcinosarcoma (inhibition of growth 
by doxorubicin has constituted 65.0 ± 5.8%) and resistant 
variants of this tumor (inhibition of growth has constituted 
30.0 ± 2.7% and 2.1 ± 0.5%, respectively) have been 
studied.
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Mitochondria study. Oxidative phosphorylation 
indices of tumor cell mitochondria were determined 
accor ding [11]. The mitochondrial transmembrane 
electrochemical gradient (Δψm) was measured using JC-
1-staining [12].
Analysis of mitochondrial transmembrane poten-
tial. The mitochondrial transmembrane electrochemical 
gradient (Δψm) was measured using JC-1. JC-1, a cell 
permeable, cationic, lipophilic dye freely crosses the mi-
tochondrial membrane and forms J-aggregates which 
fluoresce red; accordingly, viable cells with a normal 
mitochondrial membrane potential when stained with 
JC-1 exhibit a pronounced orange fluorescence (FL2). 
Following an apoptotic stimulus, the resultant decrease 
in the mitochondrial membrane potential prevents 
JC-1 from entering the mitochondria and remains 
as monomers in the cytosol that emits a predominantly 
green fluorescence (FL1). Therefore, the ratio of J-ag-
gregates/monomers serves as an effective indicator 
of the cellular mitochondrial transmembrane potential, 
allowing apoptotic cells to be easily distinguished from 
their non-apoptotic counterparts. Briefly, Walker-256 cells 
(2.5•105/ml) were stained with JC-1 (7.5 mM in PBS, 
10 min, 37 °C). Cells were then acquired in a flow cytometer 
on the basis of quadrant plot to distinguish monomers from 
J-aggregates. To set the quadrants, cells were treated with 
H2O2 (20 mM, 37 °C, 30 min), representative of cells with 
depolarized mitochondrial membrane potential. The flow 
cytometer “Coulter Epics XL” (Beckman Coulter, USA) 
was used in studies.
Determination of biochemical indices 
in blood serum and homogenates of tumor tissue 
of the  Walker-256 carcinosarcoma, level of potassium, 
magnesium, lactate, glucose, activities of lactate dehy-
drogenase and glucose-6-phosphate dehydrogenase 
has been performed with the help of biochemical and 
immune-enzyme analyzer “GBG ChemWell 2990” (GBG, 
USA) using standard kits for this equipment.
Statistical processing of the data was performed 
by the use of the software Statistica (v. 7.0) and Stu-
dent’s t-criterion. A statistically significant difference was 
considered to be present at p < 0.05.
RESULTS AND DISCUSSION
As stated above, the problem of drug resistance of ma-
lignant tumors is one of the most significant in oncology. 
For this reason, in our studies we primarily have paid atten-
tion to the processes of glycolysis and oxidative phospho-
rylation, which are the main sources of energy and plastic 
material for biosynthetic reactions of cell [13]. On the other 
hand, during the development of drug resistance, we have 
determined level of some ions, which characterize water-
salt metabolism of cells, both in organism and tumor. 
The main biological role of electrolytes consists in their 
osmotic action, in maintenance of electrical neutrality 
in biological fluids and tissues of organism and in their 
impact on enzyme reactions in cells. At the same time, 
first of all we have evaluated level of К+ and Mg++ in blood 
serum and tumor in the process of induction of doxoru-
bicin resistance of the Walker-256 carcinosarcoma. К+ 
is one of the key element of water-salt metabolism. Its 
level in orga nism significantly increases when malignant 
process occurs. Moreover, tumor tissue is also characte-
rized by increased concentration of potassium ions [9].
Magnesium is one of the key cations required for 
enzyme reactions [8, 13]. For instance, for the activity 
of DNA-polymerase and phosphofructokinase, allosteric 
enzyme of glycolysis, ions of Mg++ are highly required. 
In general, magnesium is required for reactions with as-
sistance of most of phosphokinases.
In the result of carried out studies, the following data 
concerning concentration of potassium ions in peripheral 
blood serum have been obtained (Fig. 1). It has been 
determined that in blood serum of rats with parental 
Walker-256 carcinosarcoma, concentration of К+ was 
significantly higher, than in intact (control) animals that 
corresponds with data of literature [9]. However, du ring 
development of resistance of tumor to doxorubicin, 
concentration of potassium ions in serum starts gradu-
ally decreasing, and in tumor, though insignificantly, 
but gradually increasing (see Fig. 1). This is probably 
connected with the fact that resistant tumor requires 
more К+ and more impacts the water-salt metabolism 
in organism, than parental (more sensitive to doxorubicin) 
Walker-256 carcinosarcoma. Probably, content of water 
in organism with resistant tumor is higher, than in organism 
with sensitive tumor.
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Fig. 1. Potassium levels in blood serum and tumor tissue supernatant 
of animals with Walker-256 carcinosarcoma during development 
of resistance to doxorubicin (*p < 0.05 compared with sensitive 
tumor-bearing rats; **p < 0.05 compared with sensitive tumor)
The same data have been obtained concerning con-
centration of magnesium ions. Concentration of Mg++ 
in blood serum of animals with sensitive Walker-256 car-
cinosarcoma is also higher, than in intact rats (Fig. 2). This 
indicates that malignant process significantly changes 
electrolyte balance in orga nism. However, with develop-
ment of tumor resistance to doxorubicin, content of this 
cation in blood serum was gradually decreasing, and 
in tumor — gradually increasing. As stated above, Mg++ 
is required for many enzyme reactions associated with 
phosphorylation and DNA synthesis. About activation 
of intracellular metabolism in the process of development 
of malignant tumors drug resistance we pointed out in our 
previous studies [14].
Development of resistance of Walker-256 carcino-
sarcoma to doxorubicin is also characterized by changes 
in energy metabolism. Firstly, we have studied, how level 
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of glucose is changed in blood serum of animals. It has 
been determined that level of this compound in blood 
serum of tumor host is significantly lower, than in intact 
rats (Fig. 3). Mentioned fact is the consequence of the fact 
that malignant tumor is characterized trap of glucose. 
As the development of resistance progressed, level 
of glucose in blood serum of animals even greater de-
creased. However, this index in tumor, while gradually 
lo sing sensitivity to the cytostatic drug, on the contrary, 
was increasing (see Fig. 3). This logically corresponds with 
dynamics of change of activity of lactate dehydrogenase 
both in blood serum and, especially, Walker-256 car-
cinosarcoma (Fig. 4). On the background of reduction 
of lactate dehydrogenase activity and, correspondingly, 
level of lactate (Fig. 5), the increase of glucose in tumor 
was observed. Such changes in mentioned indices indi-
cate gradual decrease of glycolysis activity in tumor cells 
during development of resistance to doxorubicin. At that 
pyruvate is most likely metabolized in Krebs cycle and 
to a lesser degree is used for the formation of lactate. Such 
metabolic situation can cause the activation of generation 
of Acetyl-CoA that, in turn, stimulates increase of cho-
lesterol that corresponds with the results of our previous 
studies [15, 16].
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Fig. 2. Magnesium levels in blood serum and tumor tissue superna-
tant of animals with Walker-256 carcinosarcoma during development 
of resistance to doxorubicin (*p < 0.05 compared with sensitive 
tumor-bearing rats; **p < 0.05 compared with sensitive tumor)
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Fig. 3. Glucose levels in blood serum and tumor tissue supernatant 
of animals with Walker-256 carcinosarcoma during development 
of resistance to doxorubicin (*p < 0.05 compared with sensitive 
tumor-bearing rats; **p < 0.05 compared with sensitive tumor)
Since we studied intensity of glycolysis in tumor cells, 
it would be logical to study also functional activity of mi-
tochondria. To solve this question we have used two me-
thodic approaches: polarography (oxygen consumption 
by mitochondria) and application of dye  JC-1. Data of the 
studies are represented in Fig. 6 and 7. As seen in Fig. 6, 
development of resistance of Walker-256 carcinosarcoma 
to doxorubicin causes the decrease of content of mono-
mer form JC-1 in tumor cells (FL1; green fluorescence). 
It indicates higher membrane potential of mitochondria 
and increase of functional activity of these organelles. 
These results correspond well with data of polarographic 
determination of oxygen consumption rate by mito-
chondria. As seen in Fig. 7, development of resistance 
to doxorubicin causes increase of oxygen consumption 
rate by organelles at phosphorylation of exogenous ADP 
in the presence of glutamate. However, it should be men-
tioned that despite changes of bioenergetics indices 
in development of drug resistance, intensity of glycolysis 
in tumor cells remains high, and intensity of mitochondrial 
oxidative phosphorylation — low compared with non-
transformed cells.
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Fig. 4. Lactate dehydrogenase activity in blood serum and tumor 
tissue supernatant of animals with Walker-256 carcinosarcoma 
during development of resistance to doxorubicin (*p < 0.05 com-
pared with sensitive tumor-bearing rats; **p < 0.05 compared with 
sensitive tumor)
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Fig. 5. Lactate levels in blood serum and tumor tissue supernatant 
of animals with Walker-256 carcinosarcoma during development 
of resistance to doxorubicin (*p < 0.05 compared with sensitive 
tumor-bearing rats; *p < 0.05 compared with sensitive tumor)
Since glucose is known to be able also to degra de 
by pentose phosphate pathway [13], we have studied 
activity of the first enzyme of this cycle — glucose-
6-phosphate dehydrogenase. It has been determined 
that as development of drug resistance in  Walker-256 car-
cinosarcoma progresses, gradual increase of activity 
of this enzyme occurs (Fig. 8). It is very important that 
NADP is co-enzyme for this enzyme. Pentose phosphate 
cycle plays double role in the formation of NADPH. In two 
stages of pentose phosphate cycle, oxidation of one glu-
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cose  mo lecule occurs and twelve NADPH molecules are 
formed. This component does not participate in cellular 
oxidation, but is required for the specific reduction reac-
tions, among which are reduction of glutathione, biosyn-
thesis of fatty acids and different steroid hormones [17–
19]. Pentose phosphate pathway is especially important 
for those organs and cells, in which these reactions are 
actively proceeding — adipocytes, liver, mammary gland, 
adrenal gland cortex. Moreover, regulation of water-salt 
metabolism is tightly connected with activity of pentose 
phosphate cycle. On the other hand, formation of im-
portant metabolites takes place in cycle and especially 
ribose-5-phosphate, which is precursor of nucleic acids.
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Fig. 6. The mitochondrial transmembrane electrochemical gra-
dient (Δψm) (JC-1 staining) in Walker-256 carcinosarcoma during 
development of resistance to doxorubicin
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Fig. 7. Oxygen consumption by tumor cell mitochondria during 
exogenous ADP phosphorylation (oxidation substrate — glutamate) 
(*p < 0.05 compared with sensitive tumor)
Thus, obtained data show significant changes in con-
tent of K+ and Mg++ and indices of energy metabolism 
in blood serum and in tumor cells during resistance de-
velopment of Walker-256 carcinosarcoma to doxorubi-
cin. Results of studies show that as development of drug 
resistance in blood serum of tumor host progresses, 
decrease of K+, Mg++, glucose and increase of these 
indices in tumor tissue are observed. At that gradual 
tumor’s loss of sensitivity is characterized by decrease 
of glycolysis activity in it and activation of mitochondrial 
oxidative phosphorylation and pentose phosphate way 
of glucose degradation, which causes more intensive 
formation of NADPH. Reduced NADP is required for 
many reduction reactions that is very important for pro-
tection of tumor cells from damaging agents.
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Fig. 8. Glucose-6-phosphate dehydrogenase activity 
in  Walker-256 carcinosarcoma supernatant during development of re-
sistance to doxorubicin (*p < 0.05 compared with sensitive tumor)
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